ClinicalTrials.gg
CompletedNCT00910858Updated Sep 30, 2013Results posted

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

A Phase 1/2 interventional study of Lenalidomide and Recombinant human erythropoietin in Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS), sponsored by Celgene Corporation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-30.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.

Enrollment
17th of 43
40 · median 32
Started
2005
with 2 others
Phase 1/2
7 of 44
none open now
Registered
19th of 44
by date
Lead sponsor
3 of 44
Celgene Corporation

Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 17th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2005, is one of 7 in phase 1/2, and was the 19th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing lenalidomide in Myelodysplastic Syndromes as a file.
02

Study summary

The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).

03

Conditions studied

  • Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must understand and voluntarily sign an form.
  2. Age ≥18 years at the time of signing the informed consent form.
  3. Must be able to adhere to the study visit schedule and other protocol requirements.
  4. Documented diagnosis of MDS that meets International Prognostic Scoring System (IPSS) criteria for Low- to Intermediate-1-risk disease.

    •Must have a diagnosis of low- or intermediate- risk MDS without a del 5q chromosomal abnormality (patients taking 15 mg starting dose only).

  5. Must be able to provide adequate bone marrow (BM) aspirate and specimens for histopathological analysis and standard cytogenetic analysis during the screening procedure.
  6. Red blood cell (RBC) transfusion-dependent anemia defined as having received ≥4 transfusions of RBCs within 56 days of randomization or symptomatic anemia ( \< 9.0 g/dl).
  7. Failed prior treatment with recombinant human erythropoietin (rhu-EPO) (≥ 30,000 U/week x 6) or serum erythropoietin (EPO) concentration ≥500 mU/ml (hemoglobin \< 9.0 g/dl).
  8. (ECOG) performance status score of 0, 1, or 2.
  9. Females of (FCBP) must agree to use two reliable forms of simultaneously or to practice complete abstinence from heterosexual intercourse 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device [IUD], hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods, if needed.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating females.
  2. Prior therapy with lenalidomide.
  3. Proliferative white blood cell (WBC) ≥12,000/µL) chronic myelomonocytic leukemia (CMML).
  4. MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or diseases.
  5. Any of the following lab abnormalities:

    • (ANC) \<500 cells/µL (0.5 x 10\^9/L)
    • count \<50,000/µL (50 x 10\^9/L)
    • Serum creatinine > (ULN)
    • Serum glutamic oxaloacetic transaminase/ (SGOT/AST) or serum glutamic pyruvic transaminase/alanine transaminase (SGPT/ALT) >2.0 x ULN
    • Serum total >2.0 mg/dL (34 µmol/L)
  6. Prior ≥grade-2 National Cancer Institute (NCI CTCAE) allergic reaction to thalidomide.
  7. Prior desquamating (blistering) rash while taking thalidomide.
  8. Patients with ≥grade-2 neuropathy.
  9. anemia due to factors such as iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis or gastrointestinal bleeding.
  10. Use of cytotoxic chemotherapeutic agents, erythropoietin, or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days of the first day of study drug treatment.
  11. Prior history of other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for ≥3 years.
  12. Any serious medical condition or psychiatric illness that will prevent the patient from signing the form or will place the subject at unacceptable risk if he/she participates in the study.
  13. Known (HIV-1) positivity.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    10 mg Lenalidomide

    Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.

    Drug: Lenalidomide · Drug: Recombinant human erythropoietin

  • Experimental
    15 mg Lenalidomide Non-del 5q

    Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.

    Drug: Lenalidomide · Drug: Recombinant human erythropoietin

Interventions

06

What researchers measure

Primary outcomes

  1. PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide

    Area under the plasma concentration-time curve from Time 0 to 24 hours post-dose for lenalidomide after a single dose, calculated using the log-linear trapezoidal method.

    Time frame: On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours post-dose.

  2. Monotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide

    Area under the plasma concentration-time curve from Time 0 to 5 hours postdose for lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days, calculated using the log-linear trapezoidal method.

    Time frame: On Day 14 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hours postdose.

Secondary outcomes

  1. PK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)

    The maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after a single dose on day -7.

    Time frame: On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose.

  2. Monotherapy Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)

    The Maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days.

    Time frame: On Day 14 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hours postdose.

  3. PK Phase: Terminal Half-life (t1/2)

    The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).

    Time frame: On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose.

  4. PK Phase: Percent of Administered Lenalidomide Excreted Over 24 Hours After a Single, Oral Dose

    Percent of the administered dose of lenalidomide excreted unchanged in urine over 24 hours postdose after a single dose on Day -7, calculated as: (amount excreted unchanged in urine over 24 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.

    Time frame: On Day -7 at predose and over the intervals of 0-5, 5-8, 8-12, and 12-24 hours postdose.

  5. Monotherapy Phase: Percent of Lenalidomide Excreted Over 5 Hours Post Day 14 Dose

    Percent of the administered lenalidomide dose excreted unchanged in urine over 5 hours postdose after multiple dosing for 14 days, calculated as: (amount excreted unchanged in urine over the first 5 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.

    Time frame: On Day 14, at predose and over the interval of 0-5 hours postdose.

  6. Time to Grade 4 Neutropenia or Thrombocytopenia

    Time to the first event of grade 4 neutropenia or thrombocytopenia, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0, was calculated as date of first event - date of first dose + 1.

    Time frame: From the date of first dose until 30 days after the last dose (up to 1218 days)

  7. Percentage of Participants With a Erythroid Response Across All Phases

    Erythroid response was categorized as either a major response or a minor response. A major response was defined as red blood cell (RBC) transfusion independence during any consecutive 56-day period and an increase in hemoglobin of at least 1.5 g/dL. A minor response was defined as a ≥ 50% or ≥ 4 unit decrease in RBC transfusions from pretreatment requirements (the number of RBC transfusions required over an 8-week period before the start of study drug treatment).

    Time frame: Assessed every 28 days until study discontinuation (up to 1218 days).

  8. Percentage of Participants Overall With Erythroid Response by Baseline Erythropoietin Level

    To evaluate the predictive value of pretreatment serum erythropoietin (EPO) concentration for erythroid response to lenalidomide, the percentage of erythroid responders versus non-responders were stratified by Baseline EPO levels (≤ 500 mIU/mL versus \> 500 mIU/mL). Response includes participants with either a major or minor response.

    Time frame: Assessed every 28 days until study discontinuation (up to 1218 days)

  9. Change From Baseline in Bone Marrow Cellularity and Correlation With Grade 4 Myelosuppression

    Bone marrow cellularity is the volume ratio of hematopoietic stem cells and adipocytes (fat cells). Due to the small number of bone marrow samples, this analysis was not performed.

    Time frame: Baseline and Week 16

  10. Marrow-infiltrating Lymphocyte (MIL) Number and Cytolytic Activity

    Due to the low number of bone marrow samples collected this analysis was not performed.

    Time frame: Pre-Study and Week 16

07

Results

Posted Sep 30, 2013

Participant flow

A total of 40 participants were enrolled at 1 site in this study, with 12 participants enrolled in the Pharmacokinetic (PK) Phase of the study, 39 participants enrolled in the Monotherapy Phase of the study, and 23 participants enrolled in the Combined Treatment Phase of the study.

Pharmacokinetic Phase
Participant flow — Pharmacokinetic Phase
Milestone10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5q
Started903
Completed803
Not completed100
Withdrew: Adverse event100
Monotherapy Phase
Participant flow — Monotherapy Phase
Milestone10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5q
Started17157
Safety population17157
Pharmacokinetic population1707
Completed000
Not completed17157
Withdrew: Adverse event320
Withdrew: Lack of therapeutic effect964
Withdrew: Withdrawal by subject131
Withdrew: Protocol violation100
Withdrew: Other342
Combined Treatment Phase
Participant flow — Combined Treatment Phase
Milestone10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5q
Started9104
Completed000
Not completed9104
Withdrew: Lack of therapeutic effect863
Withdrew: Withdrawal by subject020
Withdrew: Protocol violation100
Withdrew: Other021

Outcome measures

PrimaryPK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide

Area under the plasma concentration-time curve from Time 0 to 24 hours post-dose for lenalidomide after a single dose, calculated using the log-linear trapezoidal method.

Time frame:
On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours post-dose.
Reported as:
Geometric mean · ng*h/mL
PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide
ng*h/mL10 mg Lenalidomide
PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide817 ± 30.5
SecondaryPK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)

The maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after a single dose on day -7.

Time frame:
On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose.
Reported as:
Geometric mean · ng/mL
PK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
ng/mL10 mg Lenalidomide
Total Lenalidomide179 ± 33.6
S-Lenalidomide101 ± 34.9
R-Lenalidomide78.3 ± 32.7
SecondaryMonotherapy Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)

The Maximum observed plasma concentration (Cmax) of lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days.

Time frame:
On Day 14 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hours postdose.
Reported as:
Geometric mean · ng/mL
Monotherapy Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
ng/mL10 mg Lenalidomide
Total Lenalidomide185 ± 38.7
S-Lenalidomide104 ± 39
R-Lenalidomide80.7 ± 38.8
SecondaryPK Phase: Terminal Half-life (t1/2)

The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).

Time frame:
On Day -7 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose.
Reported as:
Geometric mean · hours
PK Phase: Terminal Half-life (t1/2)
hours10 mg Lenalidomide
Total Lenalidomide3.72 ± 19.5
S-Lenalidomide4.14 ± 29.0
R-Lenalidomide3.58 ± 21.4
SecondaryPK Phase: Percent of Administered Lenalidomide Excreted Over 24 Hours After a Single, Oral Dose

Percent of the administered dose of lenalidomide excreted unchanged in urine over 24 hours postdose after a single dose on Day -7, calculated as: (amount excreted unchanged in urine over 24 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.

Time frame:
On Day -7 at predose and over the intervals of 0-5, 5-8, 8-12, and 12-24 hours postdose.
Reported as:
Geometric mean · percent of administered dose
PK Phase: Percent of Administered Lenalidomide Excreted Over 24 Hours After a Single, Oral Dose
percent of administered dose10 mg Lenalidomide
Total Lenalidomide65.1 ± 13.5
S-Lenalidomide67.9 ± 13.9
R-Lenalidomide62.2 ± 14.0
SecondaryMonotherapy Phase: Percent of Lenalidomide Excreted Over 5 Hours Post Day 14 Dose

Percent of the administered lenalidomide dose excreted unchanged in urine over 5 hours postdose after multiple dosing for 14 days, calculated as: (amount excreted unchanged in urine over the first 5 hours postdose / Dose) \* 100. The dose was 10 mg for total lenalidomide and 5 mg for the enantiomers.

Time frame:
On Day 14, at predose and over the interval of 0-5 hours postdose.
Reported as:
Geometric mean · percent of administered dose
Monotherapy Phase: Percent of Lenalidomide Excreted Over 5 Hours Post Day 14 Dose
percent of administered dose10 mg Lenalidomide
Total Lenalidomide34.0 ± 60.3
S-Lenalidomide35.4 ± 59.0
R-Lenalidomide32.5 ± 62.0
SecondaryTime to Grade 4 Neutropenia or Thrombocytopenia

Time to the first event of grade 4 neutropenia or thrombocytopenia, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0, was calculated as date of first event - date of first dose + 1.

Time frame:
From the date of first dose until 30 days after the last dose (up to 1218 days)
Reported as:
Median · days
Time to Grade 4 Neutropenia or Thrombocytopenia
daysNon-del 5qDel 5q
Grade 4 Neutropenia69.0 (11 to 168)28.0 (17 to 36)
Grade 4 Thrombocytopenia53.0 (22 to 141)29.0 (22 to 36)
SecondaryPercentage of Participants With a Erythroid Response Across All Phases

Erythroid response was categorized as either a major response or a minor response. A major response was defined as red blood cell (RBC) transfusion independence during any consecutive 56-day period and an increase in hemoglobin of at least 1.5 g/dL. A minor response was defined as a ≥ 50% or ≥ 4 unit decrease in RBC transfusions from pretreatment requirements (the number of RBC transfusions required over an 8-week period before the start of study drug treatment).

Time frame:
Assessed every 28 days until study discontinuation (up to 1218 days).
Reported as:
Number · percentage of participants
Percentage of Participants With a Erythroid Response Across All Phases
percentage of participants10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5q
Major response17.640.085.7
Minor response5.900
SecondaryPercentage of Participants Overall With Erythroid Response by Baseline Erythropoietin Level

To evaluate the predictive value of pretreatment serum erythropoietin (EPO) concentration for erythroid response to lenalidomide, the percentage of erythroid responders versus non-responders were stratified by Baseline EPO levels (≤ 500 mIU/mL versus \> 500 mIU/mL). Response includes participants with either a major or minor response.

Time frame:
Assessed every 28 days until study discontinuation (up to 1218 days)
Reported as:
Number · percentage of participants
Percentage of Participants Overall With Erythroid Response by Baseline Erythropoietin Level
percentage of participantsRespondersNon-respondersOverall
Baseline EPO ≤ 500 mIU/mL62.547.853.8
Baseline EPO > 500 mIU/mL37.539.138.5
SecondaryChange From Baseline in Bone Marrow Cellularity and Correlation With Grade 4 Myelosuppression

Bone marrow cellularity is the volume ratio of hematopoietic stem cells and adipocytes (fat cells). Due to the small number of bone marrow samples, this analysis was not performed.

Time frame:
Baseline and Week 16

No measurements were reported for this outcome.

PrimaryMonotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide

Area under the plasma concentration-time curve from Time 0 to 5 hours postdose for lenalidomide (its R- and S- enantiomers and the enantiomers combined) after multiple dosing for 14 days, calculated using the log-linear trapezoidal method.

Time frame:
On Day 14 blood samples were taken at predose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hours postdose.
Reported as:
Geometric mean · ng*h/mL
Monotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide
ng*h/mL10 mg Lenalidomide
Total Lenalidomide563 ± 32.5
S-Lenalidomide315 ± 34.2
R-Lenalidomide248 ± 30.6
SecondaryMarrow-infiltrating Lymphocyte (MIL) Number and Cytolytic Activity

Due to the low number of bone marrow samples collected this analysis was not performed.

Time frame:
Pre-Study and Week 16

No measurements were reported for this outcome.

Adverse events

Collected over The safety analyses were conducted on data collected from the time of first dose of study drug to 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg Lenalidomide—10/24 (41.7%)24/24 (100%)
15 mg Lenalidomide—5/15 (33.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
Event10 mg Lenalidomide15 mg Lenalidomide
AstheniaGeneral disorders0/241/15
Pneumonia NOSInfections and infestations1/241/15
Cardiac failure congestiveCardiac disorders1/241/15
Deep vein thrombosisVascular disorders0/241/15
Urinary retentionRenal and urinary disorders0/241/15
Disease progression NOSGeneral disorders1/240/15
FatigueGeneral disorders1/240/15
ParotitisInfections and infestations1/240/15
Sepsis NOSInfections and infestations1/240/15
Myocardial infarctionCardiac disorders1/240/15
Most frequent other events
Showing 10 of 107
Most frequent other events
Event10 mg Lenalidomide15 mg Lenalidomide
NeutropeniaBlood and lymphatic system disorders22/2414/15
Leukopenia NOSBlood and lymphatic system disorders21/2412/15
ThrombocytopeniaBlood and lymphatic system disorders21/2411/15
Diarrhoea NOSGastrointestinal disorders10/2411/15
Anaemia NOSBlood and lymphatic system disorders17/249/15
PruritusSkin and subcutaneous tissue disorders9/247/15
CoughRespiratory, thoracic and mediastinal disorders4/247/15
ConstipationGastrointestinal disorders5/245/15
Dyspnoea NOSRespiratory, thoracic and mediastinal disorders2/245/15
Rash NOSSkin and subcutaneous tissue disorders7/242/15

Baseline characteristics

Age Continuous
Age Continuous(years)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
Mean67.8 ± 10.9673.4 ± 6.5172.6 ± 7.3970.8 ± 9.07
Sex: Female, Male
Sex: Female, Male(Participants)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
Female34411
Male1411328
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
White1713737
Hispanic1102
Other1102
Duration of MDS
Duration of MDS(years)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
Mean2.8 ± 2.282.6 ± 2.224.2 ± 4.743.0 ± 2.81
International Prognostic Scoring System (IPSS) Score
International Prognostic Scoring System (IPSS) Score(participants)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
Low risk (0)88218
Intermediate-1 (0.5-1.0)97521
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
02417
11411631
21001
French-American-British (FAB) classification of MDS
French-American-British (FAB) classification of MDS(participants)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
Refractory anemia (RA)67215
Refractory anemia with ringed sideroblasts (RARS)56011
Refractory anemia with excess blasts (RAEB)3148
Refractory anemia with excess blasts -1 (RAEB-1)0101
Other3014
Serum erythropoietin level
Serum erythropoietin level(participants)10 mg Non-del 5q15 mg Non-del 5q10 mg Del 5qTotal
< 500 mIU/mL94215
≥ 500 mIU/mL72514
Missing19010
08

Study locations

1 site
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
09

References and documents

Publications

  • Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct 25;120(17):3419-24. doi: 10.1182/blood-2012-03-415661. Epub 2012 Aug 30. PubMed 22936658 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Apr 2006 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 7 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2009
First posted
Jun 1, 2009
Start
Jan 2005
Primary completionActual
Apr 2006
CompletionActual
May 2009
Results first posted
Sep 30, 2013
Last update
Sep 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00910858
Responsible party
Sponsor
First posted
Jun 1, 2009
Start date
Jan 2005
Primary completion
Apr 2006
Completion
May 2009
Results posted
Sep 30, 2013
Last update
Sep 30, 2013

Study contacts

Robert Knight, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion